NO940660D0 - HLA - begrensete Hepatit B virus CTL-epitoper - Google Patents

HLA - begrensete Hepatit B virus CTL-epitoper

Info

Publication number
NO940660D0
NO940660D0 NO940660A NO940660A NO940660D0 NO 940660 D0 NO940660 D0 NO 940660D0 NO 940660 A NO940660 A NO 940660A NO 940660 A NO940660 A NO 940660A NO 940660 D0 NO940660 D0 NO 940660D0
Authority
NO
Norway
Prior art keywords
hla
ctl epitopes
virus ctl
hepatitis
restricted
Prior art date
Application number
NO940660A
Other languages
English (en)
Other versions
NO940660L (no
Inventor
Maria A Vitiello
Robert W Chesnut
Original Assignee
Cytel Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytel Corp filed Critical Cytel Corp
Publication of NO940660D0 publication Critical patent/NO940660D0/no
Publication of NO940660L publication Critical patent/NO940660L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO940660A 1991-08-26 1994-02-25 HLA - begrensete Hepatit B virus CTL-epitoper NO940660L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74956891A 1991-08-26 1991-08-26
US82768292A 1992-01-29 1992-01-29
US87449192A 1992-04-27 1992-04-27
PCT/US1992/007218 WO1993003764A1 (en) 1991-08-26 1992-08-26 Hla-restricted hepatitis b virus ctl epitopes

Publications (2)

Publication Number Publication Date
NO940660D0 true NO940660D0 (no) 1994-02-25
NO940660L NO940660L (no) 1994-04-22

Family

ID=27419385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940660A NO940660L (no) 1991-08-26 1994-02-25 HLA - begrensete Hepatit B virus CTL-epitoper

Country Status (16)

Country Link
EP (2) EP0534615B1 (no)
JP (2) JP3738395B2 (no)
AU (1) AU687725B2 (no)
BG (1) BG98523A (no)
CA (1) CA2115839C (no)
CZ (1) CZ42794A3 (no)
DE (1) DE69231621T2 (no)
ES (1) ES2155060T3 (no)
FI (1) FI940918A (no)
GR (1) GR3035575T3 (no)
HU (1) HUT68510A (no)
IL (1) IL102964A0 (no)
NO (1) NO940660L (no)
NZ (2) NZ270605A (no)
OA (1) OA09888A (no)
WO (1) WO1993003764A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
ATE342730T1 (de) * 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6235288B1 (en) 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
JP3795914B2 (ja) * 1993-04-27 2006-07-12 ユナイテッド・バイオメディカル・インコーポレイテッド ワクチン用免疫原性ｌｈｒｈペプチド構築体および合成普遍免疫刺激器
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
US6413935B1 (en) 1993-09-14 2002-07-02 Epimmune Inc. Induction of immune response against desired determinants
GB9325772D0 (en) * 1993-12-16 1994-02-16 Smithkline Beecham Biolog Novel compounds
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
EP0948533A1 (en) * 1996-12-30 1999-10-13 Innogenetics N.V. ANNEXIN V-BINDING POLYPEPTIDES DERIVED FROM HBsAg AND THEIR USES
TR199902786T2 (xx) * 1997-04-11 2000-06-21 Sangstat Medical Corporation Ba����kl�k sistemi faaliyetinin d�zene sokulmas� ve iltihaplanman�n durdurulmas� i�in lipofilik peptidlerin h�cre yap�s�n�n d�zene konulmas�.
US20010019714A1 (en) * 1998-04-07 2001-09-06 Charles D. Y. Sia Hiv-specific cytotoxic t-cell responses
US7105164B1 (en) 1998-04-07 2006-09-12 Sanofi Pasteur Limited HIV-specific cytotoxic T-cell responses
CU22871A1 (es) * 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
EP1230268B1 (en) 1999-11-18 2009-10-14 Pharmexa Inc. Heteroclitic analogs of class i epitopes
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CN1997660A (zh) * 2004-04-21 2007-07-11 芝加哥大学 肌球蛋白轻链激酶抑制剂及其使用
WO2008021295A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of hiv-1
EP2476697B1 (en) 2006-10-17 2015-06-17 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing MPHOSPH1 polypeptides
US8877206B2 (en) * 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2009129227A1 (en) * 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
WO2011015656A2 (en) 2009-08-07 2011-02-10 Transgene Sa Composition for treating hbv infection
US10076570B2 (en) 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
CN103732743B (zh) 2011-08-12 2017-03-15 肿瘤疗法科学股份有限公司 Mphosph1肽及包含它们的疫苗
WO2013036201A1 (en) * 2011-09-06 2013-03-14 Agency For Science, Technology And Research Polypeptide vaccine
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
CA2840974A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
CA2840937A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
EP3336186A4 (en) 2015-08-12 2019-03-06 OncoTherapy Science, Inc. PEPTIDE DERIVED FROM DEPDC1 AND VACCINE CONTAINING SAME
NZ740816A (en) * 2015-09-08 2022-05-27 Univ Zuerich Compositions against cat allergy
EP3360885A4 (en) 2015-10-08 2019-04-24 Oncotherapy Science, Inc. PEPTIDE DERIVED FROM MPHOSPH1 AND VACCINE CONTAINING SAME
WO2017083820A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935235A (en) * 1979-05-24 1990-06-19 The Regents Of The University Of California Non-passageable viruses
US5017558A (en) * 1980-01-14 1991-05-21 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
JPS60161999A (ja) * 1984-02-02 1985-08-23 Chemo Sero Therapeut Res Inst ペプチド
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
IT1238343B (it) * 1989-10-16 1993-07-13 Cesalpino Andrea Fond Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
CA2072351A1 (en) * 1990-01-05 1991-07-06 Andrew J. Mcmichael Hiv-1 core protein fragments

Also Published As

Publication number Publication date
WO1993003764A1 (en) 1993-03-04
NZ244103A (en) 1997-07-27
CZ42794A3 (en) 1994-11-16
OA09888A (en) 1994-09-15
DE69231621T2 (de) 2001-05-31
FI940918A0 (fi) 1994-02-25
DE69231621D1 (de) 2001-02-08
JPH06510051A (ja) 1994-11-10
EP1018344A3 (en) 2000-09-20
BG98523A (en) 1995-05-31
CA2115839A1 (en) 1993-03-04
JP3586278B2 (ja) 2004-11-10
EP0534615A3 (en) 1994-05-25
AU687725B2 (en) 1998-03-05
JP2004075693A (ja) 2004-03-11
NZ270605A (en) 1997-07-27
IL102964A0 (en) 1993-01-31
GR3035575T3 (en) 2001-06-29
JP3738395B2 (ja) 2006-01-25
EP0534615A2 (en) 1993-03-31
EP0534615B1 (en) 2001-01-03
NO940660L (no) 1994-04-22
HUT68510A (en) 1995-06-28
AU2548792A (en) 1993-03-16
EP1018344A2 (en) 2000-07-12
CA2115839C (en) 2010-06-01
FI940918A (fi) 1994-04-08
HU9400581D0 (en) 1994-05-30
ES2155060T3 (es) 2001-05-01

Similar Documents

Publication Publication Date Title
NO940660D0 (no) HLA - begrensete Hepatit B virus CTL-epitoper
NO914401D0 (no) Fotodetektor
ATE139382T1 (de) Direkte phasendigitalisierung
DE69126606T2 (de) Vakzine
FI923443A (fi) Foereningar och foerfarande foer inhibering av hiv och liknande virus
DE69214888D1 (de) Phasenfehlerprozessor
NO930699D0 (no) Hoeyeffektiv vaeske/vaeske hydrosyklon
DE69200189D1 (de) Phasendetektor.
FI950567A (fi) Hepatitis A-virusrokote
DK0555292T3 (da) Hvirvelstrømsventil
DE69028322T2 (de) Positionsdetektor
FI934777A (fi) Multipel hepatitis b virus ytproteiner som bildar partiklar
DE3377401D1 (de) Non-a, non-b hepatitis antigen
DE69128681D1 (de) Fokusdetektor
ZA926441B (en) HLA-restricted hepatitis B virus CTL epitopes.
FI943929A0 (fi) Hepatiitti C-viruspeptidejä
NO933600D0 (no) Termostabile virus
ZA912581B (en) Hepatitis c virus epitopes
FI971702A0 (fi) Hepatiitti-C-viruksen asialoglykoproteiinit
KR930004128U (ko) 가두리 양식용 통발
KR920001945U (ko) 절첩식 틀체
BR7100638U (pt) Mini-album fotografico
KR930005974U (ko) 가두리 양식용 통발
KR920007857U (ko) 유모차
SE9001365D0 (sv) Detektor